H. Ishihara

Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough

A. Niimi, H. Hida, H. Ishihara, 2019, Airway pharmacology and treatment.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

S. Birring, J. Smith, K. Chung, 2022, Lung.

Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough

T. Kamei, A. Niimi, M. Shinkai, 2021, European Respiratory Journal.

A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis

S. Konno, Y. Uchio, Yuki Kato, 2018, Journal of pain research.

Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough

M. Machida, Yoshiyuki Tsuda, H. Hida, 2020 .

Phase 2a Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a P2x3 Receptor Antagonist S-600918: Effects on Health-Related Quality of Life in Patients with Refractory Chronic Cough

A. Niimi, H. Hida, H. Ishihara, 2020 .